More recently, it has been shown that NOD/SCID mice carrying nonfunctional IL-2 receptor gamma chain (NOD/SCID/γcnull, NOG) are more permissive recipients than NOD/SCID and can be easily xenografted with human MM cell lines to produce a disease similar to that seen in patients, including multiple metastatic sites and bone lesions [ 24, 25].
Particularly, patients with multiple metastatic lesions benefit from bone-targeting therapeutic radiopharmaceuticals. Agents utilizing beta-emitting radionuclides in routine clinical praxis are, for example, [89Sr]SrCl2 and [153Sm]Sm-EDTMP.
Patients with adenocarcinoma metastatic to the liver, multiple visceral involvement and extensive metastatic bone disease were considered as unfavorable.
After the exclusion of 86 patients with pathological HF (metastatic bone cancer, multiple myeloma, Paget's disease) or primary hyperparathyroidism and 15 patients in whom data were incomplete, a total of 746 patients (536 women and 210 men) were included in the analysis.
13 In brief, we utilized the Canberra Hospital electronic administrative database to identify patients discharged with a diagnosis of HF and excluded all readmissions and reoperations, as well as patients with pathological HF (primary or metastatic bone cancer, multiple myeloma, or Paget's disease).
80%% of all patients had multiple metastatic sites, 18 % had bone metastases, 21 % had visceral or local metastases, and 62%% had both.
We report the outcomes of MRONJ managed with PENT-E in patients with metastatic bone disease or multiple myeloma.
The pivotal regulator of osteoclastic activity is the system osteoprotegerin (OPG /receptor activator of NF- κB (RANK /RANK-ligand (RANK /RANK-ligandet al, 2004), which is involved in physiological as well as pathological conditions, such as metastatic bone disease and multiple myeloma (Chikatsu et al, 2000; Lipton et al, 2002; PaRANKL al, 2003; Vanderkerken et al, 2003).
Randomised controlled trials (RCTs) have given contradictory results about the efficacy and safety of ibandronate in treating metastatic bone disease (MBD) or multiple myeloma.
